APO Research
Talk to an analyst

APO RESEARCH · REPORT

Poxviridae Infections Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Poxviridae Infections Drug Market Outlook and Growth Opportunities 2026

26 December 2025192 pages

Choose your research edition.

Industry ResearchPoxviridae Infections Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Poxviridae Infections Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Poxviridae Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Poxviridae Infections Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Poxviridae Infections Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Poxviridae Infections Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Poxviridae Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Poxviridae Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Poxviridae Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Poxviridae Infections Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Poxviridae Infections Drug market include Takeda Pharmaceutical Company Limited, China Biologic Products, Inc., Verrica Pharmaceuticals Inc., Tonix Pharmaceuticals Holding Corp., SIGA Technologies, Inc., N & N Pharmaceuticals Inc., EpiVax, Inc., CJ HealthCare Corp. and Chimerix, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Poxviridae Infections Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Poxviridae Infections Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Poxviridae Infections Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Poxviridae Infections Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Poxviridae Infections Drug Segment by Company

Takeda Pharmaceutical Company Limited

China Biologic Products, Inc.

Verrica Pharmaceuticals Inc.

Tonix Pharmaceuticals Holding Corp.

SIGA Technologies, Inc.

N & N Pharmaceuticals Inc.

EpiVax, Inc.

CJ HealthCare Corp.

Chimerix, Inc.

CEL-SCI Corporation

BioFactura, Inc.

Bavarian Nordic A/S

Poxviridae Infections Drug Segment by Type

CJ-40011

BA-368

24a

Others

Poxviridae Infections Drug Segment by Application

Hospital

Clinic

Others

Poxviridae Infections Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Poxviridae Infections Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Poxviridae Infections Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Poxviridae Infections Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Poxviridae Infections Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Poxviridae Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Poxviridae Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Poxviridae Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Poxviridae Infections Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Poxviridae Infections Drug industry.

Chapter 3: Detailed analysis of Poxviridae Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Poxviridae Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Poxviridae Infections Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Poxviridae Infections Drug Industry Trends Table 2. Poxviridae Infections Drug Industry Drivers Table 3. Poxviridae Infections Drug Industry Opportunities and Challenges Table 4. Poxviridae Infections Drug Industry Restraints Table 5. Global Poxviridae Infections Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Poxviridae Infections Drug Revenue Share by Company (2021-2026) Table 7. Global Poxviridae Infections Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Poxviridae Infections Drug Sales Volume Share by Company (2021-2026) Table 9. Global Poxviridae Infections Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Poxviridae Infections Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Poxviridae Infections Drug Key Company Manufacturing Base & Headquarters Table 12. Global Poxviridae Infections Drug Company, Product Type & Application Table 13. Global Poxviridae Infections Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Poxviridae Infections Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of CJ-40011 Table 18. Significant Companies of BA-368 Table 19. Significant Companies of 24a Table 20. Significant Companies of Others Table 21. Global Poxviridae Infections Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Poxviridae Infections Drug Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Poxviridae Infections Drug Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Poxviridae Infections Drug Sales Volume Share by Type (2021-2026) Table 25. Global Poxviridae Infections Drug Sales Volume Share by Type (2027-2032) Table 26. Global Poxviridae Infections Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Poxviridae Infections Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Poxviridae Infections Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Poxviridae Infections Drug Sales Value Share by Type (2021-2026) Table 30. Global Poxviridae Infections Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Poxviridae Infections Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Poxviridae Infections Drug Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Poxviridae Infections Drug Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Poxviridae Infections Drug Sales Volume Share by Application (2021-2026) Table 38. Global Poxviridae Infections Drug Sales Volume Share by Application (2027-2032) Table 39. Global Poxviridae Infections Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Poxviridae Infections Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Poxviridae Infections Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Poxviridae Infections Drug Sales Value Share by Application (2021-2026) Table 43. Global Poxviridae Infections Drug Sales Value Share by Application (2027-2032) Table 44. Global Poxviridae Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Poxviridae Infections Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Poxviridae Infections Drug Sales Market Share by Region (2021-2026) Table 47. Global Poxviridae Infections Drug Sales by Region (2027-2032) & (K Units) Table 48. Global Poxviridae Infections Drug Sales Market Share by Region (2027-2032) Table 49. Global Poxviridae Infections Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Poxviridae Infections Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Poxviridae Infections Drug Sales Value Share by Region (2021-2026) Table 52. Global Poxviridae Infections Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Poxviridae Infections Drug Sales Value Share by Region (2027-2032) Table 54. Global Poxviridae Infections Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Poxviridae Infections Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Poxviridae Infections Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Poxviridae Infections Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 59. Global Poxviridae Infections Drug Sales Market Share by Country (2021-2026) Table 60. Global Poxviridae Infections Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Poxviridae Infections Drug Sales Market Share by Country (2027-2032) Table 62. Global Poxviridae Infections Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Poxviridae Infections Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Poxviridae Infections Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Poxviridae Infections Drug Sales Value Market Share by Country (2027-2032) Table 66. Takeda Pharmaceutical Company Limited Company Information Table 67. Takeda Pharmaceutical Company Limited Business Overview Table 68. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Portfolio Table 70. Takeda Pharmaceutical Company Limited Recent Development Table 71. China Biologic Products, Inc. Company Information Table 72. China Biologic Products, Inc. Business Overview Table 73. China Biologic Products, Inc. Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. China Biologic Products, Inc. Poxviridae Infections Drug Product Portfolio Table 75. China Biologic Products, Inc. Recent Development Table 76. Verrica Pharmaceuticals Inc. Company Information Table 77. Verrica Pharmaceuticals Inc. Business Overview Table 78. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio Table 80. Verrica Pharmaceuticals Inc. Recent Development Table 81. Tonix Pharmaceuticals Holding Corp. Company Information Table 82. Tonix Pharmaceuticals Holding Corp. Business Overview Table 83. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Portfolio Table 85. Tonix Pharmaceuticals Holding Corp. Recent Development Table 86. SIGA Technologies, Inc. Company Information Table 87. SIGA Technologies, Inc. Business Overview Table 88. SIGA Technologies, Inc. Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. SIGA Technologies, Inc. Poxviridae Infections Drug Product Portfolio Table 90. SIGA Technologies, Inc. Recent Development Table 91. N & N Pharmaceuticals Inc. Company Information Table 92. N & N Pharmaceuticals Inc. Business Overview Table 93. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio Table 95. N & N Pharmaceuticals Inc. Recent Development Table 96. EpiVax, Inc. Company Information Table 97. EpiVax, Inc. Business Overview Table 98. EpiVax, Inc. Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. EpiVax, Inc. Poxviridae Infections Drug Product Portfolio Table 100. EpiVax, Inc. Recent Development Table 101. CJ HealthCare Corp. Company Information Table 102. CJ HealthCare Corp. Business Overview Table 103. CJ HealthCare Corp. Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. CJ HealthCare Corp. Poxviridae Infections Drug Product Portfolio Table 105. CJ HealthCare Corp. Recent Development Table 106. Chimerix, Inc. Company Information Table 107. Chimerix, Inc. Business Overview Table 108. Chimerix, Inc. Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Chimerix, Inc. Poxviridae Infections Drug Product Portfolio Table 110. Chimerix, Inc. Recent Development Table 111. CEL-SCI Corporation Company Information Table 112. CEL-SCI Corporation Business Overview Table 113. CEL-SCI Corporation Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. CEL-SCI Corporation Poxviridae Infections Drug Product Portfolio Table 115. CEL-SCI Corporation Recent Development Table 116. BioFactura, Inc. Company Information Table 117. BioFactura, Inc. Business Overview Table 118. BioFactura, Inc. Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. BioFactura, Inc. Poxviridae Infections Drug Product Portfolio Table 120. BioFactura, Inc. Recent Development Table 121. Bavarian Nordic A/S Company Information Table 122. Bavarian Nordic A/S Business Overview Table 123. Bavarian Nordic A/S Poxviridae Infections Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Bavarian Nordic A/S Poxviridae Infections Drug Product Portfolio Table 125. Bavarian Nordic A/S Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Poxviridae Infections Drug Distributors List Table 129. Poxviridae Infections Drug Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Poxviridae Infections Drug Product Image Figure 2. Global Poxviridae Infections Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Poxviridae Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Poxviridae Infections Drug Sales (2021-2032) & (K Units) Figure 5. Global Poxviridae Infections Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Poxviridae Infections Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. CJ-40011 Image Figure 10. BA-368 Image Figure 11. 24a Image Figure 12. Others Image Figure 13. Global Poxviridae Infections Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Poxviridae Infections Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Poxviridae Infections Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Poxviridae Infections Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Poxviridae Infections Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Poxviridae Infections Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Poxviridae Infections Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Poxviridae Infections Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Poxviridae Infections Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Poxviridae Infections Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Poxviridae Infections Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Poxviridae Infections Drug Sales Value Share by Application (2021-2032) Figure 28. Global Poxviridae Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Poxviridae Infections Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Poxviridae Infections Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Poxviridae Infections Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Poxviridae Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Poxviridae Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Poxviridae Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Poxviridae Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Poxviridae Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Poxviridae Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Poxviridae Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Poxviridae Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Poxviridae Infections Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Poxviridae Infections Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Poxviridae Infections Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Poxviridae Infections Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Poxviridae Infections Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • CJ-40011
  • BA-368
  • 24a
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda Pharmaceutical Company Limited
  • China Biologic Products, Inc.
  • Verrica Pharmaceuticals Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • SIGA Technologies, Inc.
  • N & N Pharmaceuticals Inc.
  • EpiVax, Inc.
  • CJ HealthCare Corp.
  • Chimerix, Inc.
  • CEL-SCI Corporation
  • BioFactura, Inc.
  • Bavarian Nordic A/S

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Poxviridae Infections Drug Sales Value (2021-2032)
  4. 1.2.2 Global Poxviridae Infections Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Poxviridae Infections Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Poxviridae Infections Drug Market Dynamics
  1. 2.1 Poxviridae Infections Drug Industry Trends
  2. 2.2 Poxviridae Infections Drug Industry Drivers
  3. 2.3 Poxviridae Infections Drug Industry Opportunities and Challenges
  4. 2.4 Poxviridae Infections Drug Industry Restraints
3 Poxviridae Infections Drug Market by Company
  1. 3.1 Global Poxviridae Infections Drug Company Revenue Ranking in 2025
  2. 3.2 Global Poxviridae Infections Drug Revenue by Company (2021-2026)
  3. 3.3 Global Poxviridae Infections Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Poxviridae Infections Drug Average Price by Company (2021-2026)
  5. 3.5 Global Poxviridae Infections Drug Company Ranking (2024-2026)
  6. 3.6 Global Poxviridae Infections Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Poxviridae Infections Drug Company Product Type and Application
  8. 3.8 Global Poxviridae Infections Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Poxviridae Infections Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Poxviridae Infections Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Poxviridae Infections Drug Market by Type
  1. 4.1 Poxviridae Infections Drug Type Introduction
  2. 4.1.1 CJ-40011
  3. 4.1.2 BA-368
  4. 4.1.3 24a
  5. 4.1.4 Others
  6. 4.2 Global Poxviridae Infections Drug Sales Volume by Type
  7. 4.2.1 Global Poxviridae Infections Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Poxviridae Infections Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Poxviridae Infections Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Poxviridae Infections Drug Sales Value by Type
  11. 4.3.1 Global Poxviridae Infections Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Poxviridae Infections Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Poxviridae Infections Drug Sales Value Share by Type (2021-2032)
5 Poxviridae Infections Drug Market by Application
  1. 5.1 Poxviridae Infections Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Poxviridae Infections Drug Sales Volume by Application
  6. 5.2.1 Global Poxviridae Infections Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Poxviridae Infections Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Poxviridae Infections Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Poxviridae Infections Drug Sales Value by Application
  10. 5.3.1 Global Poxviridae Infections Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Poxviridae Infections Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Poxviridae Infections Drug Sales Value Share by Application (2021-2032)
6 Poxviridae Infections Drug Regional Sales and Value Analysis
  1. 6.1 Global Poxviridae Infections Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Poxviridae Infections Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Poxviridae Infections Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Poxviridae Infections Drug Sales by Region (2027-2032)
  5. 6.3 Global Poxviridae Infections Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Poxviridae Infections Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Poxviridae Infections Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Poxviridae Infections Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Poxviridae Infections Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Poxviridae Infections Drug Sales Value (2021-2032)
  12. 6.6.2 North America Poxviridae Infections Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Poxviridae Infections Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Poxviridae Infections Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Poxviridae Infections Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Poxviridae Infections Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Poxviridae Infections Drug Sales Value (2021-2032)
  21. 6.9.2 South America Poxviridae Infections Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Poxviridae Infections Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Poxviridae Infections Drug Sales Value Share by Country, 2025 VS 2032
7 Poxviridae Infections Drug Country-level Sales and Value Analysis
  1. 7.1 Global Poxviridae Infections Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Poxviridae Infections Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Poxviridae Infections Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Poxviridae Infections Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Poxviridae Infections Drug Sales by Country (2027-2032)
  6. 7.4 Global Poxviridae Infections Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Poxviridae Infections Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Poxviridae Infections Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Poxviridae Infections Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Poxviridae Infections Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Poxviridae Infections Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company Limited
  2. 8.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 8.2 China Biologic Products, Inc.
  8. 8.2.1 China Biologic Products, Inc. Company Information
  9. 8.2.2 China Biologic Products, Inc. Business Overview
  10. 8.2.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 China Biologic Products, Inc. Poxviridae Infections Drug Product Portfolio
  12. 8.2.5 China Biologic Products, Inc. Recent Developments
  13. 8.3 Verrica Pharmaceuticals Inc.
  14. 8.3.1 Verrica Pharmaceuticals Inc. Company Information
  15. 8.3.2 Verrica Pharmaceuticals Inc. Business Overview
  16. 8.3.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
  18. 8.3.5 Verrica Pharmaceuticals Inc. Recent Developments
  19. 8.4 Tonix Pharmaceuticals Holding Corp.
  20. 8.4.1 Tonix Pharmaceuticals Holding Corp. Company Information
  21. 8.4.2 Tonix Pharmaceuticals Holding Corp. Business Overview
  22. 8.4.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Portfolio
  24. 8.4.5 Tonix Pharmaceuticals Holding Corp. Recent Developments
  25. 8.5 SIGA Technologies, Inc.
  26. 8.5.1 SIGA Technologies, Inc. Company Information
  27. 8.5.2 SIGA Technologies, Inc. Business Overview
  28. 8.5.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 SIGA Technologies, Inc. Poxviridae Infections Drug Product Portfolio
  30. 8.5.5 SIGA Technologies, Inc. Recent Developments
  31. 8.6 N & N Pharmaceuticals Inc.
  32. 8.6.1 N & N Pharmaceuticals Inc. Company Information
  33. 8.6.2 N & N Pharmaceuticals Inc. Business Overview
  34. 8.6.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
  36. 8.6.5 N & N Pharmaceuticals Inc. Recent Developments
  37. 8.7 EpiVax, Inc.
  38. 8.7.1 EpiVax, Inc. Company Information
  39. 8.7.2 EpiVax, Inc. Business Overview
  40. 8.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 EpiVax, Inc. Poxviridae Infections Drug Product Portfolio
  42. 8.7.5 EpiVax, Inc. Recent Developments
  43. 8.8 CJ HealthCare Corp.
  44. 8.8.1 CJ HealthCare Corp. Company Information
  45. 8.8.2 CJ HealthCare Corp. Business Overview
  46. 8.8.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CJ HealthCare Corp. Poxviridae Infections Drug Product Portfolio
  48. 8.8.5 CJ HealthCare Corp. Recent Developments
  49. 8.9 Chimerix, Inc.
  50. 8.9.1 Chimerix, Inc. Company Information
  51. 8.9.2 Chimerix, Inc. Business Overview
  52. 8.9.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Chimerix, Inc. Poxviridae Infections Drug Product Portfolio
  54. 8.9.5 Chimerix, Inc. Recent Developments
  55. 8.10 CEL-SCI Corporation
  56. 8.10.1 CEL-SCI Corporation Company Information
  57. 8.10.2 CEL-SCI Corporation Business Overview
  58. 8.10.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 CEL-SCI Corporation Poxviridae Infections Drug Product Portfolio
  60. 8.10.5 CEL-SCI Corporation Recent Developments
  61. 8.11 BioFactura, Inc.
  62. 8.11.1 BioFactura, Inc. Company Information
  63. 8.11.2 BioFactura, Inc. Business Overview
  64. 8.11.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 BioFactura, Inc. Poxviridae Infections Drug Product Portfolio
  66. 8.11.5 BioFactura, Inc. Recent Developments
  67. 8.12 Bavarian Nordic A/S
  68. 8.12.1 Bavarian Nordic A/S Company Information
  69. 8.12.2 Bavarian Nordic A/S Business Overview
  70. 8.12.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bavarian Nordic A/S Poxviridae Infections Drug Product Portfolio
  72. 8.12.5 Bavarian Nordic A/S Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Poxviridae Infections Drug Value Chain Analysis
  2. 9.1.1 Poxviridae Infections Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Poxviridae Infections Drug Sales Mode & Process
  6. 9.2 Poxviridae Infections Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Poxviridae Infections Drug Distributors
  9. 9.2.3 Poxviridae Infections Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst